← Leaderboards
Gregory John Tobin
Biological Mimetics, Inc.
$10,932,769
Attributed
$10,932,769
Total exposure
9
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,932,769 · 9
By mechanism
R44$7,273,546 · 2
R43$2,160,582 · 6
N43$1,498,641 · 1
Top collaborators
No co-investigators on record.
Most similar at Biological Mimetics, Inc.
Same institution · by research overlap
- Stephen Jeffrey Dollery$1,106,201
Others in their field
Top investigators on “Future”
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Gary D Acton · University Of California-Davis$320,373,312
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$274,284,003
- Chanza Baytop · Westat, Inc.$271,217,917
- Everette D Joseph · Howard University$246,289,043
Research focus
FutureVirusProductionTechnologyPathogenEngineeringVaccinesImmunogenicityEpitopesSiteDoseSerumDesignAnimalsNeutralizing AntibodyInfectionClinical TrialsPreparationBaseRunningLicensingSafetyImmunizationProteins
Grant awards (17)
FAST â CRISPR-based Diagnostic for Parasites$1,498,641
N43 · FY2025 · AI · contact PI
An instrument-free malaria diagnostic$291,139
R43 · FY2025 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$917,012
R44 · FY2024 · AI · contact PI
An instrument-free malaria diagnostic$297,761
R43 · FY2024 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$976,542
R44 · FY2023 · AI · contact PI
Nonclinical Development of an Improved Polio Vaccine$990,662
R44 · FY2022 · AI · contact PI
Development of a cross-protective HRV vaccine$224,958
R43 · FY2019 · AI · contact PI
Development of an improved, low-cost polio vaccine (Ir-IPV)$723,136
R44 · FY2018 · AI · contact PI
Manganese-peptide Countermeasures for Radiation Exposure$299,372
R43 · FY2018 · AI · contact PI
Improved RSV F Vaccine Candidates$224,956
R43 · FY2018 · AI · contact PI
Development of an improved, low-cost polio vaccine (Ir-IPV)$743,104
R44 · FY2017 · AI · contact PI
Development of the first HRV vaccine$999,998
R44 · FY2016 · AI · contact PI
Development of the first HRV vaccine$999,998
R44 · FY2015 · AI · contact PI
Development of a New Low-Cost Poliovirus Vaccine (Ir-IPV): Feasibility study with PV-2$224,887
R43 · FY2015 · AI · contact PI
Development of the first HRV vaccine$923,094
R44 · FY2014 · AI · contact PI
Development of a novel human rhinovirus vaccine$299,164
R43 · FY2011 · AI · contact PI
Development of a novel human rhinovirus vaccine$298,345
R43 · FY2010 · AI · contact PI